Reported positive results from aleniglipron Phase 2 ACCESS II study with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point and potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results